Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

COVID-19 Severe Pneumonia Clinical Trial

— COVIDOLIP  

Official title:

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04435223
• Other study ID #: NGUYEN AOIc 2020
• Status: Completed
• Start date: April 7, 2020
• Est. completion date: May 7, 2020

Study information

• Verified date: June 2020
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: May 7, 2020
• Est. primary completion date: May 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 2 of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (>=38 °C) Hypothermia (< 35°C) AND new radiologic pulmonary infiltrate

• At admission or within 48 hours following hospital admission

• With 2 qSOFA criteria: MAP =< 100 mmHg, Respiratory Rate >= 22, Glasgow score < 15 OR on mechanical ventilation OR under vasopressor

• Age > 18

• affiliated to social security

Exclusion Criteria:

• Pregnancy

• immunodepression

• Pathology known to cause severe lymphopenia

• hospitalisation within 3 month before inclusion AND sepsis

Related Conditions & MeSH terms

• COVID-19 Severe Pneumonia
• Pneumonia
• Severe Pneumonia Due to Other Pathogene

Intervention

Biological:
• biological assays in particular on the lipid metabolism
bioassays carried out on samples already collected and conserved

Locations

Country	Name	City	State
France	Chu Dijon Bourgogne	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cholesterol concentration		Within 48 hours following hospital admission
Secondary	LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.	Ventilator free days (28 days)	Within 48 hours following hospital admission